Co-Diagnostics Inc. on Friday signed an agreement for CoSara Diagnostics Pvt. Ltd, to expand its commercial and distribution territory across South Asia to include Bangladesh, Pakistan, Nepal, and Sri Lanka.

CoSara is the Indian joint venture between Co-Dx and Ambalal Sarabhai Enterprises Limited.

Co-Diagnostics, most recently, regained NASDAQ listing compliance.

The expansion significantly increases CoSara's addressable market across South Asia, bringing the total regional opportunity to an estimated $13 billion based on internal analyses and third-party market data.

It also supports CoSara's plans to commercialize the CoSara PCR Pro point-of-care instrument and tests, as well as the SARAGENE product line across the region, subject to applicable regulatory approvals.

Don't Miss:

This AI Helps Fortune 1000 Brands Avoid Costly Ad Mistakes — See Why Investors Are Paying Attention

Explore the Fire-Safe Energy Storage Company With $185M in Contracted Revenue

As part of this expansion, CoSara is working to establish distribution channels in these newly added markets, including evaluating regulatory pathways, identifying priority customer segments, and engaging regional distribution partners.

Mohal Sarabhai, CEO of CoSara, commented, "South Asia represents a large and rapidly growing market for molecular diagnostics, with a significant need for easily accessible, non-invasive, quick, and reliable testing solutions.”

“Expanding our territory allows us to begin building relationships with regional partners and positions us to support the future commercialization of the point-of-care PCR platform across these markets, increasing access to molecular tests for tuberculosis, HPV, and upper respiratory infections." Co-Diagnostics CEO Dwight Egan added.

Trending: This Startup Thinks It Can Reinvent the Wheel — Literally

"This expansion reflects our broader strategy of establishing regional infrastructure ahead of product commercialization. By building local manufacturing and distribution capabilities in key regions, including the United States, South Asia, and the Middle East and North Africa, we are positioning Co-Dx to support scalable, global deployment of our PCR point-of-care platform and drive long-term growth," Egan commented.

To support these efforts, CoSara plans to host a virtual distributor information session in the second quarter of 2026, followed by an in-person distributor meeting and training event later this summer.

In March, Co-Diagnostics announced a Japanese patent covering Co-Dx PCR platform technologies.

Read Next: 

1.5 Million Users Are Already Working Inside This AI Platform — Investors Can Still Get In

It’s no wonder Jeff Bezos holds over $250 million in art — this alternative asset has outpaced the S&P 500 since 1995, delivering an average annual return of 11.4%. Here’s how everyday investors are getting started.

Image via Shutterstock

UNLOCKED: 5 NEW TRADES EVERY WEEK. Click now to get top trade ideas daily, plus unlimited access to cutting-edge tools and strategies to gain an edge in the markets.

Get the latest stock analysis from Benzinga:

APPLE (AAPL): Free Stock Analysis Report

TESLA (TSLA): Free Stock Analysis Report

This article EXCLUSIVE: Co-Diagnostics Expands South Asia Reach, Targets $13 Billion Market Opportunity originally appeared on Benzinga.com